Navigation Links
Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting
Date:12/7/2007

CHESHIRE, Conn., Dec. 7 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab), a treatment for patients with PNH, will be presented at the 2007 American Society of Hematology Meeting, December 8 - 11 in Atlanta.

The following abstracts will be presented in a poster session on red cell regulation and disorders of production on Monday, December 10, 2007. The session will open at 10:30 a.m. and poster presentations will be held from 5:00 to 7:00 p.m. for each abstract. Additional information can be accessed through the links provided below.

-- Poster # 897-III: "High Incidence of Progression to Chronic Renal

Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria

(PNH)" Dr. Peter Hillmen et al.

-- Location: Hall B3 and B4

-- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5416

-- Poster # 891-III: "Sustained Improvements in Transfusion

Requirements, Fatigue and Thrombosis with Eculizumab Treatment in

Paroxysmal Nocturnal Hemoglobinuria" Dr. Gerard Socie et al.

-- Location: Hall B3 and B4

-- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5204

-- Poster # 902-III: "Disease-Related Symptoms Reported across a Broad

Population of Patients with Paroxysmal Nocturnal Hemoglobinuria" Dr.

Gabrielle Meyers et al.

-- Location: Hall B3 and B4

-- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5438.

The following abstract will be presented in an oral session on red cell regulation and disorders of production on Tuesday, December 11, 2007. The abstract and presentation information can be accessed at the link provided below.

-- Publication Number 840: "Significant Disease Burden in Paroxysmal

Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis,

Mild Anemia and Minimal Transfusion: Clinical Improvement with

Eculizumab Therapy" Dr. Monica Bessler et al.

-- Location: Rooms B213-B214

-- Tuesday, December 11, 2007 - 8:45 a.m.

-- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5302.


'/>"/>
SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Alexion Pharmaceuticals Invites You to Participate in its Third Quarter 2007 Results Conference Call and Web Cast
2. Alexion to Present at Investor Conferences
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2017)... Opelousas, LA (PRWEB) , ... July 23, 2017 ... ... providers to interact, thus improving communication, safety and patient-provider relationships. New tools are ... according to results of the 19th Annual Health Care’s Most Wired® survey, released ...
(Date:7/23/2017)... ... July 23, 2017 , ... ... Florida Pain Relief Group – Melbourne, a practice owned by Physician Partners of ... interventional pain management, Dr. Stern also is certified in pediatrics, emergency medicine and ...
(Date:7/23/2017)... ... ... Viora Ltd., a leading medical aesthetics solutions manufacturer, is ... United States Patent and Trademark Office. The patent applies to treatments with Viora’s ... mechanisms to further increase the efficacy and safety of final treatment results for ...
(Date:7/22/2017)... , ... July 22, 2017 , ... ... year with the majority of patients not requiring pain medication after three months ... Sports Medicine’s Annual Meeting today in Toronto, Ontario, Canada found that those ...
(Date:7/21/2017)... PITTSBURGH, PA (PRWEB) , ... July 21, 2017 , ... ... I use a lot of pleural catheters available on the market," said an inventor ... level of comfort and safety for the patient." , He developed the patent-pending PLEURAL ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017  The global market for ... of approximately $394.1 million in 2016.  Although in early ... solid growth, in particular as a result of the ... and the recent introduction of a significant number of ... less-invasive testing of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing a ... who suffer from painful intercourse and other painful pelvic pain conditions such ... to menopause. ... LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a void ...
(Date:7/10/2017)... , July 10, 2017  US medical equipment and ... 2021, according to Medical Equipment & Supplies: ... Freedonia Focus Reports. Continued increases in demand for medical ... of the population and supported by gains in disposable ... and supplies. New product introductions will also drive sales ...
Breaking Medicine Technology: